INKT News and Press, MiNK Therapeutics Inc. From 08/17/22

Gainers: Blue Water Vaccines ( BWV ) +57% . Eargo ( EAR ) +49% . Cassava Sciences ( SAVA ) +29% . MiNK Therapeutics ( INKT ) +24% . Cogent Biosciences ( COGT ) +16% . Losers: Blueprint Medicines ( BPMC ) -22% ....

Gainers: Artelo Biosciences ( ARTL ) +31% . Ventyx Biosciences ( VTYX ) +23% . Eargo ( EAR ) +19% . Fulcrum Therapeutics ( FULC ) +18% . Genprex ( GNPX ) +17% . Losers: Albireo Pharma ( ALBO ) -25% . Sema4...

Save Foods ( SVFD ) -35% on pricing of $4.8M stock offering . Albireo Pharma ( ALBO ) -23% on Q2 earnings release . Tremor International ( TRMR ) -17% on Q2 earnings release . GAN ( GAN ) -17% on Q2 earnings release . Hel...

Gainers: Liberty TripAdvisor Holdings ( LTRPB ) +107% . Magic Empire Global Limited ( MEGL ) +94% . Viridian Therapeutics ( VRDN ) +54% . Qurate Retail ( QRTEB ) +43% . Intelligent Living Application Group ( ILAG ) +36% . MiN...

MiNK Therapeutics, Inc. (INKT) Q2 2022 Earnings Conference Call August 09, 2022, 11:00 AM ET Company Participants Kimberly Ha - Head of Investor Relations Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accountin...

MiNK Therapeutics press release ( NASDAQ: INKT ): Q2 GAAP EPS of -$0.18. The company ended the second quarter 2022 with a cash balance of $29.8 million as compared to $38.9 million at December 31, 2021. For further details see: MiNK Thera...

Novel stromal-CAR-iNKT shows activity in solid tumors; FIH planned for 2023 Clinical presentation of AgenT-797 in solid tumors, myeloma, and ARDS planned for 2H2022 Under the leadership team of Dr. Joy Zhou, completed internal cGMP production of AgenT-797 with expansio...

NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-m...

NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-m...

iNKT cells have unique properties that could be therapeutic. MiNK Therapeutics has shown it can both manufacture and engineer iNKT cells. Preliminary data expected before year-end could push the stock price substantially higher. For further details see: MiNK Therapeutics...